Advertisement
Australia markets close in 29 minutes

  • ALL ORDS

    7,836.30
    -101.20 (-1.28%)
     

  • ASX 200

    7,575.50
    -107.50 (-1.40%)
     

  • AUD/USD

    0.6536
    +0.0013 (+0.20%)
     

  • OIL

    84.04
    +0.47 (+0.56%)
     

  • GOLD

    2,348.40
    +5.90 (+0.25%)
     

  • Bitcoin AUD

    98,436.38
    +179.76 (+0.18%)
     

  • CMC Crypto 200

    1,387.45
    +4.88 (+0.35%)
     

  • AUD/EUR

    0.6091
    +0.0018 (+0.30%)
     

  • AUD/NZD

    1.0964
    +0.0006 (+0.06%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,695.77
    +411.23 (+2.38%)
     

  • NIKKEI 225

    38,047.45
    +418.97 (+1.11%)
     

Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

Brian Orelli, PhD and Keith Speights, The Motley Fool
·3-min read

Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.

Continue reading